KMT2A and pancreatic neoplasm: Inhibition of MLL1, a PD-L1 transcriptional activator, in combination with an anti-PD-L1 or an anti-PD-1 antibody, effectively suppresses pancreatic tumor growth in a FasL- and CTL-dependent manner [35].